
THE McGILL UNIVERSITY ROSALIND & MORRIS GOODMAN
CANCER RESEARCH CENTRE
PRESENTS
WEDNESDAY, JUNE 6, 2018
McGill University, Roddick Gates
GALA 2018
Wednesday, June 6, 2018
McGill University, Roddick Gates
845 SHERBROOKE ST. WEST, MONTREAL (QUEBEC)
The biennial Goodman Cancer Research Gala, one of the largest and most prestigious events on Montreal’s social calendar, raises much-needed funds to support innovative cancer research at the Rosalind & Morris Goodman Cancer Research Centre (GCRC) at McGill University.
The 2018 Gala supported the Rosalind and Morris Goodman Cancer Research Centre and celebrated its commitment to the Lung Cancer Network.
Event highlights
6:00 PM Cocktails
7:00 PM Dinner and dancing
Our focus
The biennial Goodman Cancer Research Gala, one of the largest and most prestigious events on Montreal’s social calendar, raises much-needed funds to support innovative cancer research.
This year, the Gala supports the Rosalind & Morris Goodman Cancer Research Centre and celebrates its commitment to a Lung Cancer Network.
A Lung Cancer
Network
The GCRC is committed to the creation of a Lung Cancer Network, a paradigm-shifting initiative
that will bring together local clinical and research institutions in a collaborative model to tackle the challenges of lung cancer and metastatic disease.
The Goodman Cancer Research Centre is proud to play a pivotal role in this network by delivering research outcomes supported by advanced technology platforms and highly trained research professionals.
Through collaboration, we will leverage knowledge, expertise, resources, and strategies, and multiply successes.
A Lung Cancer Network will
facilitate collaboration among basic and clinician-scientists, clinicians, and patients leading to new approaches to understand lung cancer in the non-smoking population
improve prevention, diagnosis, and treatments for lung cancer
become one of the premier lung oncology networks with local, national, and international partnerships
The network’s core activities include state-of-the-art diagnosis and treatment, specialized diagnostic tests, cutting-edge translational research in lung cancer treatment, and expanding the cancer biorepository, as well as crucial clinical trial networks and metrics centered on improving outcomes.
